These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: Value of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography scan versus diagnostic contrast computed tomography in initial staging of pediatric patients with lymphoma.
    Author: Cheng G, Servaes S, Zhuang H.
    Journal: Leuk Lymphoma; 2013 Apr; 54(4):737-42. PubMed ID: 22957898.
    Abstract:
    Our objective was to evaluate the value of (18)F-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography/computed tomography (PET/CT) versus diagnostic contrast CT in the initial staging of pediatric Hodgkin disease (HD) and non-Hodgkin lymphoma (NHL). Thirty patients with HD and 21 patients with NHL were included in this retrospective study. On nodal lesion analysis, PET/CT detected 94.8% (HD) and 88.3% (NHL) of total lesions, respectively, in contrast to 82.6% (HD) and 69.1% (NHL), respectively, for diagnostic contrast CT. PET/CT also detected more extranodal lesions. On the patient level, PET/CT detected additional lesions in 50% of patients with HD and in 42.9% of patients with NHL. In contrast, diagnostic contrast CT detected additional lesions in 16.7% (HD) and 23.8% (NHL) of total cases. FDG PET/CT led to upstaging in seven cases of HD and seven cases of NHL, while diagnostic contrast CT upstaged two cases of NHL. We conclude that FDG PET/CT outperforms diagnostic contrast CT in the initial staging of pediatric patients with lymphoma.
    [Abstract] [Full Text] [Related] [New Search]